ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annu...(for efficacy as a twice-a-day and once-a...),Health

In a separate poster presentation titled "Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Tearing at 8 Hours Following Dosing in a Multi-Site Clinical Trial Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis", ISTA demonstrated positive results from a multi-center, double-masked, placebo-controlled, clinical study with 86 patients who were randomized to receive either Bepreve 1.5% or placebo in both eyes in three CAC tests spaced two weeks apart. The results showed Bepreve 1.5% was statistically superior to placebo for at least 8 hours after ophthalmic dosing for reducing CAC-induced tearing.

In another poster presentation titled "The Safety of the Anti-Histamine Bepotastine Besilate Ophthalmic Solution in a Healthy Pediatric Population from Ten to Seventeen Years of Age", ISTA demonstrated Bepreve 1.5% dosed in both eyes twice daily for six weeks was safe in a healthy pediatric population from 10-17 years of age. The pediatric subjects in this age group (n = 45) were among 861 patients enrolled in this masked, randomized, placebo-controlled clinical trial, with a randomization of 2:1 (Bepreve 1.5%:placebo). The proportion of subjects in the Bepreve 1.5% treatment group with an adverse event (22.5%) was very similar to that seen for subjects instilling placebo (20.0%). No serious adverse events were reported during the clinical trial for any pediatric subject.

Earlier in the week, the Company presented additional results from clinical studies with Bepreve 1.0%, as well as data from a clinical study with the Company's Xibrom(TM) (bromfenac ophthalmic solution 0.09%) product and laboratory results with Vitrase(R) (hyaluronidase injection). The results were presented in the following poster presentations:

Bepotastine Besilate Ophthalmic Solution 1.0% Rapidly Reduces Conjunctival
'/>"/>